Related Experiment Video
Updated: Jun 10, 2026
Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Transcoronary bone marrow-derived progenitor cells in a child with myocardial infarction: first pediatric experience
Alisa Limsuwan1, Pavit Pienvichit, Thosaphol Limpijankit
1Division of Pediatric Cardiology, Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. alimsuwan@yahoo.com
Insights
This study shows that transcoronary stem cell therapy using bone marrow-derived progenitor cells safely improved cardiac function in a pediatric patient with heart failure. This offers a promising new treatment for pediatric end-stage heart disease.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Pediatric Cardiology
Background:
- Congestive heart failure in children post-myocardial infarction presents a significant clinical challenge.
- Adult stem cell therapies show promise for cardiac repair, but pediatric applications are less explored.
Observation:
- A 9-year-old girl with refractory heart failure post-myocardial infarction underwent transcoronary autologous stem cell transplantation.
- Bone marrow-derived progenitor cells (CD133+/CD34+ >90%) were isolated and administered via transcoronary catheter.
- The procedure was performed without complications.
Findings:
- Cardiac function significantly improved 3 months post-transplantation, with left ventricular ejection fraction increasing from 30% to 47%.
- Improvements were confirmed by cardiac magnetic resonance and echocardiogram.
Implications:
- This is the first reported pediatric case of successful transcoronary stem cell injection for end-stage heart disease.
- Transcoronary stem cell transplantation is a safe and feasible treatment option for pediatric heart failure patients.
Background:
Recent advances in stem cell therapy to restore cardiac function have great promise for patients with congestive heart failure after myocardial infarction in an adult population.
Objective:
We examined the benefits of bone marrow-derived progenitor cells treatment modality for the pediatric patient.
Methods And Results:
We present our first case of transcoronary autologous stem cell transplantation in a 9-year-old girl with refractory congestive heart failure secondary to myocardial infarction 1 year after transcatheter revascularization. The child received daily injections of granulocyte colony-stimulating factor for 3 days prior to the bone marrow aspiration. The bone marrow cells were isolated to constitute CD133+/CD34+ more than 90% of the total number. Subsequently, the progenitor cell suspension was injected via a transcoronary catheter without any complication. Three months after stem cell therapy, her cardiac function, assessed by both cardiac magnetic resonance and echocardiogram, has been improved with the left ventricular ejection fraction at 47% compared to the baseline of 30%.
Conclusion:
This is the first reported pediatric case of successful transcoronary injection of bone marrow-derived progenitor cells for end-stage heart disease. The procedure is considered safe and feasible for the pediatric population.
More Related Videos
11:37Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
Published on: June 18, 2018
07:50Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
